Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GO GUT: Golimumab in early axial spondyloarthritis and gut inflammation
2017-001728-23Phase 3Completed
- Sponsor
- Ghent University
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of golimumab in axial spondyloarthritis (axSpA), sponsored by Ghent University. Primary endpoint: Clinical remission. Started May 2017; status: completed.
02
Drugs
golimumab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2017-001728-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001728-23.